Home > Pulmonology > ERS 2019 > Best of the Posters > Fever During Immunotherapy for NSCLC Associated with Shorter PFS

Fever During Immunotherapy for NSCLC Associated with Shorter PFS

Presented By
Dr Osamu Kanai, Kyoto Medical Centre, Japan
ERS 2019

A Japanese trial that investigated the relationship between immunotherapy efficacy and fever suggests a negative impact on disease control and progression free survival (PFS) in non-small-cell lung cancer (NSCLC) patients [1].

Dr Osamu Kanai (Kyoto Medical Centre, Japan) and his fellow researchers questioned the status of fever, an immune-related adverse event, as an advantageous factor [1]. Thus, their single-centre, retrospective study was intended to examine the connection between fever and immune-treatment of NSCLC. NSCLC patients (n=105) were studied from their first dose of nivolumab to their second dose or over 3 weeks. Fever was defined by a 0.2-0.5°C difference between axillary and oral temperature and values over 37°C or a 1°C rise.

Primary outcome to measure treatment efficacy was PFS. In addition, disease control and response rate were evaluated. All patients were also reviewed for concomitant use of corticosteroids, and non-steroidal an...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on